Evidence map›Paper›PMID 35269665›Full record

ArticleInternational journal of molecular sciences2022

Pioglitazone-Loaded PLGA Nanoparticles: Towards the Most Reliable Synthesis Method.

Biagio Todaro, Aldo Moscardini, Stefano Luin

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Recent Advances in Nanoparticle-Mediated Antibacterial Photodynamic Therapy.International journal of molecular sciences · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. How Advanced Is Nanomedicine for Atherosclerosis?International journal of nanomedicine · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Multiscale physics-basedFrontiers in drug delivery · 2024
    Review
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Biagio TodaroNational Enterprise for NanoScience and NanoTechnology (NEST) Laboratory, Scuola Normale Superiore, Piazza San Silvestro 12, I-56127 Pisa, Italy.ORCID 0000-0002-4519-7543
Aldo MoscardiniNational Enterprise for NanoScience and NanoTechnology (NEST) Laboratory, Scuola Normale Superiore, Piazza San Silvestro 12, I-56127 Pisa, Italy.
Stefano LuinNational Enterprise for NanoScience and NanoTechnology (NEST) Laboratory, Scuola Normale Superiore, Piazza San Silvestro 12, I-56127 Pisa, Italy.ORCID 0000-0003-2673-366X

Funding

Fondazione Pisa project Nanotechnology for tumor molecular fingerprinting and early diagnosis, RST 148/16Scuola Normale Superiore SNS16C_B_LUIN, SNS_RB_LUIN, SNS19_A_LUIN
6 · The paper itself

Abstract

Recent findings have proved the benefits of Pioglitazone (PGZ) against atherosclerosis and type 2 diabetes. Since the systematic and controllable release of this drug is of significant importance, encapsulation of this drug in nanoparticles (NPs) can minimize uncontrolled issues. In this context, drug delivery approaches based on several poly(lactic-co-glycolic acid) (PLGA) nanoparticles have been rising in popularity due to their promising capabilities. However, a fully reliable and reproducible synthetic methodology is still lacking. In this work, we present a rational optimization of the most critical formulation parameters for the production of PGZ-loaded PLGA NPs by the single emulsification-solvent evaporation or nanoprecipitation methods. We examined the influence of several variables (e.g., component concentrations, phases ratio, injection flux rate) on the synthesis of the PGZ-NPs. In addition, a comparison of these synthetic methodologies in terms of nanoparticle size, polydispersity index (PDI), zeta potential (ζ

Indexed as

Diabetes Mellitus, Type 2NanoparticlesDrug CarriersHumansParticle SizePioglitazonePolylactic Acid-Polyglycolic Acid CopolymerDrug CarriersPioglitazonePolylactic Acid-Polyglycolic Acid Copolymerdrug loadingdrug release kineticsencapsulation efficiencynanoprecipitationpioglitazonePLGApolymeric nanoparticles synthesissingle emulsification-solvent evaporation

Identifiers

PMID35269665
PMCPMC8910508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.